Analyzing the pricing of dental membranes and bone graft substitutes is crucial for assessing market competitiveness, profit margins, and value positioning. It allows for the identification of key cost drivers, optimization of pricing strategies, and effective adaptation to market fluctuations. SK...Read More »
November 4, 2025
To provide a subscription-based monthly monitoring service that tracks key trends and developments in the durable medical equipment market, including product approvals, HCPCS code updates, indication changes, FDA submission and approval timelines, and evolving market trends. The subscription can b...Read More »
November 4, 2025
Implantable glucose sensors represent the future of diabetes monitoring. They can be considered a long-lasting, fully implanted option that supersedes the need for both fingerstick blood glucose monitoring (BGM) and short-wear transcutaneous continuous glucose monitors (CGMs). The insertion of the...Read More »
November 3, 2025
Nipocalimab (Imaavy), developed by Johnson & Johnson’s Janssen Pharmaceuticals, represents a groundbreaking advancement in the field of immunology as a first-in-class neonatal Fc receptor (FcRn) antagonist. Designed to selectively block IgG recycling, it offers precise modulation of auto...Read More »
November 3, 2025
Pegozafermin (BIO89-100), developed by 89bio, Inc., is an advanced glycoPEGylated fibroblast growth factor 21 (FGF21) analog designed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). By enhancing insulin sensitivity, promoting lipid metabolism, and r...Read More »
November 3, 2025
Depemokimab (GSK3511294), developed by GlaxoSmithKline, is an innovative ultra–long-acting monoclonal antibody targeting interleukin-5 (IL-5) for the treatment of severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), conditions driven by Type-2 inflammation affect...Read More »
November 3, 2025
Dental implants are crucial in modern dentistry as they provide a durable and natural-looking solution for tooth replacement, improving oral functionality, aesthetics, and patient quality of life. The market is led by major players such as Dentsply Sirona, Institut Straumann AG, Nobel Biocare (Env...Read More »
November 3, 2025
The 3D and 4D-printed dental implants transform restorative dentistry by enabling patient-specific, high-precision implants with enhanced osseointegration and mechanical performance. Key drivers include the rising demand for personalized treatments, advancements in biocompatible materials, and int...Read More »
October 31, 2025
Vosevi, a combination therapy of Sofosbuvir, Velpatasvir, and Voxilaprevir, developed by Gilead Sciences, has played a pivotal role in the treatment of chronic hepatitis C. Its high efficacy across all six genotypes of the virus has contributed to its success in the antiviral market. As the patent...Read More »
October 30, 2025
The bone and joint health supplements market is entering a new phase of evolution, shaped by preventive healthcare trends, functional nutrition, and shifting consumer demographics. While North America and Western Europe remain mature markets with high brand penetration, emerging regions such as As...Read More »
October 30, 2025
The carrier screening market is experiencing significant growth, driven by the rising incidence of genetic disorders such as cystic fibrosis, sickle cell disease (SCD), and Tay-Sachs disease. There are nearly 10,000 known single-gene disorders, also called monogenic disorders, resulting from mutat...Read More »
October 29, 2025
The spatial omics industry encompassing spatial transcriptomics, proteomics, metabolomics, and epigenomics has evolved from a research niche into a strategic frontier for life sciences innovation. The market is driven by rapid adoption in translational research, oncology, and tissue-level single-c...Read More »
October 29, 2025
The animal health industry is highly competitive, dominated by a few global players with broad product portfolios and strong R&D capabilities. Leading companies such as Zoetis, MSD Animal Health, Elanco, Boehringer Ingelheim, and Ceva Santé Animale collectively hold a majority of the ma...Read More »
October 29, 2025
Edoxaban, marketed as Savaysa and Lixiana, is an oral, selective factor Xa inhibitor developed by Daiichi Sankyo that has transformed anticoagulation therapy for stroke prevention in atrial fibrillation and treatment of venous thromboembolism. Approved in more than 40 countries, it offers convenie...Read More »
October 29, 2025
The next generation wound dressings are evolving with the increasing prevalence of chronic wounds, and rising demand for effective home-based care. Emerging technologies such as hydrocolloid, foam, hydrogel, alginate, antimicrobial, sensor-integrated dressing, AI, and cloud-based platforms are tra...Read More »
October 28, 2025
Aficamten, developed by Cytokinetics, Inc., is an novel oral cardiac myosin inhibitor targeting hypertrophic cardiomyopathy (HCM), a genetic heart condition affecting roughly 1 in 500 individuals globally. By selectively modulating cardiac myosin activity, Aficamten reduces excessive contractility...Read More »
October 28, 2025
Tolebrutinib, developed by Sanofi, is an innovative oral Bruton's tyrosine kinase (BTK) inhibitor targeting multiple sclerosis (MS), a chronic autoimmune disease affecting approximately 2.5 million people worldwide. By selectively modulating neuroinflammatory pathways, Tolebrutinib addresses both ...Read More »
October 28, 2025
Ponatinib, marketed as Iclusig, is an oral tyrosine kinase inhibitor developed by Takeda Pharmaceuticals, primarily indicated for chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), particularly in patients resistant or intolerant to other th...Read More »
October 28, 2025
Sofosbuvir (Sovaldi), developed by Gilead Sciences, is a nucleotide analog inhibitor that transformed Hepatitis C Virus (HCV) treatment with high cure rates and short treatment durations. Approved in over 100 countries, it is used both as monotherapy and in combination regimens for pan-genotypic c...Read More »
October 27, 2025
Insulin glargine, marketed under the brand names Lantus and Toujeo by Sanofi, has been a key player in the management of diabetes for many years. Lantus, a long-acting insulin, has been widely used for the treatment of type 1 and type 2 diabetes, helping patients maintain stable blood glucose leve...Read More »
October 27, 2025